PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33751333-4	2021	The topical treatment with the novel TRPV1 antagonist, diosmetin (1%; 15 mg/ear), reduced ear oedema, MPO activity, and MIP-2 and IL-1beta cytokines levels by 82 +- 8%, 59 +- 10%, 40 +- 12%, and 85 +- 9%, respectively.	diosmetin	55-64	chemokine (C-X-C motif) ligand 2	Mus musculus	120-125